Table 2. Cox hazard regression analysis of overall survival.
| Overall survival | |||
|---|---|---|---|
| Variable | HR | 95% CI | p |
| Gender | 1.012 | 0.554-1.848 | 0.969 |
| Age | 1.489 | 0.808-2.744 | 0.201 |
| Preoperative ECOG performance status | 1.731 | 1.059-2.828 | 0.029 |
| Preoperative Karnofsky index | 0.973 | 0.943-1.004 | 0.087 |
| Type of surgery (resection) | 1.268 | 0.755-2.130 | 0.369 |
| Tumor location | 1.010 | 0.819-1.245 | 0.925 |
| Postoperative Karnofsky index | 0.938 | 0.901-0.977 | 0.002 |
| Postoperative radiotherapy | 0.128 | 0.056-0.293 | 0.001 |
| Postoperative chemotherapy | 0.419 | 0.217-0.807 | 0.009 |
| Temozolomide | 0.626 | 0.333-1.176 | 0.146 |
| Alkylating nitrosourea compounds (CCNU, BCNU) | 0.611 | 0.218-1.714 | 0.349 |
| PCV | 0.117 | 0.016-0.857 | 0.035 |
| Interval between surgery and postoperative treatment | 0.774 | 0.381-1.573 | 0.479 |
Bold = statistical significance; 95% CI = 95% confidence interval; HR = hazard ratio; p = p value; ECOG = Eastern Cooperative Oncology Group score; CCNU = lomustine; BCNU = carmustine; PCV = procarbazine, lomustine, vincristine